RayKnowChina Research Map
Shortlist

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌ESCC

A cancer that usually starts in cells on the surface of the middle and lower parts of the oesophagus.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
192

with a paper from 2016–2025 or a registered study

cities
67

where those hospitals are

open trials in China
190

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 69% of the world's English-language research papers on oesophageal squamous cell carcinoma, 2021–2025 (56% in 2016–2020), and 55% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

192 hospitals in 67 cities

Order: papers led on oesophageal squamous cell carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 3 papers or 1 trial on oesophageal squamous cell carcinoma, or was a site in 3 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Shanghai18
  2. Beijing12
  3. Guangzhou11
  4. Chongqing7
  5. Hangzhou6
  6. Jinan6
  7. Zhengzhou6
  8. Fuzhou5
  9. Nanjing5
  10. Shijiazhuang5

Each opens oesophageal squamous cell carcinoma in that city. 57 more cities are in the menu below.

  1. 184 papers led
  2. 137 papers led
  3. 123 papers led
  4. 82 papers led
  5. 79 papers led
  6. 71 papers led
  7. 66 papers led
  8. 65 papers led
  9. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    56 papers led
  10. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    50 papers led
  11. 50 papers led
  12. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    49 papers led
  13. 47 papers led
  14. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    41 papers led
  15. Shanghai Chest Hospital

    上海市胸科医院Shanghai

    40 papers led
  16. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    36 papers led
  17. 32 papers led
  18. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    32 papers led
  19. 31 papers led
    No open trial led
  20. 29 papers led
    No open trial led
  21. 29 papers led
  22. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    27 papers led
    No open trial led
  23. 26 papers led
    No open trial led
  24. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    25 papers led
  25. 23 papers led
    No open trial led
  26. 22 papers led
    No open trial led
  27. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    22 papers led
  28. 22 papers led
    No open trial led
  29. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    22 papers led
  30. Xijing Hospital

    空军军医大学西京医院Xi'an

    22 papers led
    No open trial led
  31. 20 papers led
  32. 20 papers led
    No open trial led
  33. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    20 papers led
    No open trial led
  34. 19 papers led
    No open trial led
  35. 18 papers led
  36. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    18 papers led
    No open trial led
  37. Anyang Tumor Hospital

    安阳市肿瘤医院Anyang

    17 papers led
    No open trial led
  38. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    17 papers led
  39. 15 papers led
    No open trial led
  40. 13 papers led
    No open trial led
  41. 13 papers led
    No open trial led
  42. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    13 papers led
  43. 12 papers led
    No open trial led
  44. 12 papers led
    No open trial led
  45. 12 papers led
  46. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    12 papers led
    No open trial led
  47. 12 papers led
    No open trial led
  48. 12 papers led
  49. 12 papers led
    No open trial led
  50. 11 papers led
    No open trial led
  51. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    11 papers led
    No open trial led
  52. 11 papers led
    No open trial led
  53. Taizhou Hospital, Wenzhou Medical University

    温州医科大学附属台州医院Taizhou

    11 papers led
    No open trial led
  54. 10 papers led
    No open trial led
  55. 10 papers led
    No open trial led
  56. 10 papers led
    No open trial led
  57. 10 papers led
  58. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    10 papers led
  59. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    10 papers led
  60. 9 papers led
    No open trial led
  61. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    9 papers led
    No open trial led
  62. 9 papers led
    No open trial led
  63. 9 papers led
    No open trial led
  64. 8 papers led
    No open trial led
  65. 8 papers led
    No open trial led
  66. 8 papers led
  67. 8 papers led
    No open trial led
  68. 8 papers led
  69. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    8 papers led
  70. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    8 papers led
    No open trial led
  71. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    8 papers led
  72. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    8 papers led
  73. Xiangya Hospital

    中南大学湘雅医院Changsha

    8 papers led
    No open trial led
  74. 7 papers led
    No open trial led
  75. Cancer Hospital CAMS – Shenzhen

    中国医学科学院肿瘤医院深圳医院Shenzhen

    7 papers led
    No open trial led
  76. 7 papers led
    No open trial led
  77. 7 papers led
    No open trial led
  78. 7 papers led
    No open trial led
  79. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    7 papers led
    No open trial led
  80. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    7 papers led
  81. Longhua Hospital

    上海中医药大学附属龙华医院Shanghai

    7 papers led
    No open trial led
  82. 7 papers led
    No open trial led
  83. 7 papers led
    No open trial led
  84. 7 papers led
    No open trial led
  85. Xiang'an Hospital, Xiamen University

    厦门大学附属翔安医院Xiamen

    7 papers led
    No open trial led
  86. 6 papers led
    No open trial led
  87. Beijing Anzhen Hospital

    首都医科大学附属北京安贞医院Beijing

    6 papers led
    No open trial led
  88. Eye Hospital of Wenzhou Medical University

    温州医科大学附属眼视光医院Wenzhou

    6 papers led
    No open trial led
  89. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    6 papers led
    No open trial led
  90. 6 papers led
    No open trial led
  91. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    6 papers led
    No open trial led
  92. Taihe Hospital

    十堰市太和医院Shiyan

    6 papers led
    No open trial led
  93. 5 papers led
    No open trial led
  94. 5 papers led
    No open trial led
  95. 5 papers led
  96. 5 papers led
    No open trial led
  97. 5 papers led
    No open trial led
  98. 5 papers led
    No open trial led
  99. 5 papers led
    No open trial led
  100. 5 papers led
    No open trial led
  101. 5 papers led
    No open trial led
  102. 5 papers led
    No open trial led
  103. 5 papers led
    No open trial led
  104. 5 papers led
    No open trial led
  105. 5 papers led
    No open trial led
  106. 4 papers led
    No open trial led
  107. 4 papers led
    No open trial led
  108. Central Hospital Affiliated to Shandong First Medical University

    山东第一医科大学附属中心医院(济南市中心医院)Jinan

    4 papers led
    No open trial led
  109. 4 papers led
    No open trial led
  110. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    4 papers led
    No open trial led
  111. 4 papers led
    No open trial led
  112. 4 papers led
    No open trial led
  113. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    4 papers led
    No open trial led
  114. 4 papers led
    No open trial led
  115. 4 papers led
  116. Renmin Hospital

    十堰市人民医院Shiyan

    4 papers led
    No open trial led
  117. 4 papers led
    No open trial led
  118. 4 papers led
    No open trial led
  119. 4 papers led
  120. Shanghai Ninth People's Hospital

    上海交通大学医学院附属第九人民医院Shanghai

    4 papers led
    No open trial led
  121. Shantou Central Hospital

    汕头市中心医院Shantou

    4 papers led
    No open trial led
  122. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    4 papers led
    No open trial led
  123. Xuzhou Central Hospital

    徐州市中心医院Xuzhou

    4 papers led
    No open trial led
  124. 4 papers led
    No open trial led
  125. 4 papers led
    No open trial led
  126. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    4 papers led
    No open trial led
  127. 3 papers led
    No open trial led
  128. 3 papers led
    No open trial led
  129. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    3 papers led
    No open trial led
  130. Fengxian District Central Hospital

    上海市奉贤区中心医院Shanghai

    3 papers led
    No open trial led
  131. 3 papers led
    No open trial led
  132. 3 papers led
    No open trial led
  133. 3 papers led
    No open trial led
  134. 3 papers led
    No open trial led
  135. 3 papers led
    No open trial led
  136. 3 papers led
    No open trial led
  137. Fourth Affiliated Hospital of Soochow University

    苏州大学附属第四医院(独墅湖医院)Suzhou

    3 papers led
    No open trial led
  138. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    3 papers led
    No open trial led
  139. Huaian Hospital

    淮安市淮安医院Huai'an

    3 papers led
    No open trial led
  140. Nanozyme Medical Center

    郑州大学基础医学院纳米酶医学中心Zhengzhou

    3 papers led
    No open trial led
  141. 3 papers led
    No open trial led
  142. 3 papers led
    No open trial led
  143. 3 papers led
    No open trial led
  144. Shanghai General Hospital

    上海市第一人民医院Shanghai

    3 papers led
    No open trial led
  145. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    3 papers led
    No open trial led
  146. 3 papers led
    No open trial led
  147. Third Affiliated Hospital of Chongqing Medical University

    重庆医科大学附属第三医院(方大医院)Chongqing

    3 papers led
    No open trial led
  148. Tongji Hospital

    同济大学附属同济医院Shanghai

    3 papers led
    No open trial led
  149. 2 papers led
    No open trial led
  150. 2 papers led
  151. 2 papers led
    No open trial led
  152. 2 papers led
    No open trial led
  153. 2 papers led
    No open trial led
  154. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    2 papers led
  155. 2 papers led
    No open trial led
  156. 2 papers led
    No open trial led
  157. 2 papers led
  158. 2 papers led
    No open trial led
  159. 2 papers led
    No open trial led
  160. Zhongshan Hospital, Xiamen University

    厦门大学附属中山医院Xiamen

    2 papers led
    No open trial led
  161. 1 paper led
  162. 1 paper led
    No open trial led
  163. 1 paper led
    No open trial led
  164. 1 paper led
    No open trial led
  165. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    1 paper led
    No open trial led
  166. 1 paper led
  167. 1 paper led
  168. 1 paper led
    No open trial led
  169. 1 paper led
    No open trial led
  170. Huadong Hospital, Fudan University

    复旦大学附属华东医院Shanghai

    1 paper led
  171. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    1 paper led
    No open trial led
  172. 1 paper led
    No open trial led
  173. 1 paper led
    No open trial led
  174. 1 paper led
    No open trial led
  175. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    1 paper led
    No open trial led
  176. 1 paper led
    No open trial led
  177. Yunnan Cancer Hospital

    云南省肿瘤医院Kunming

    1 paper led
    No open trial led
  178. An Qiu People's Hospital

    安丘市人民医院Weifang

    0 papers led
    No open trial led
  179. 0 papers led
    No open trial led
  180. 0 papers led
  181. Fei Cheng People's Hospital

    肥城市人民医院

    0 papers led
    No open trial led
  182. Heping Hospital, Changzhi Medical College

    长治医学院附属和平医院Changzhi

    0 papers led
    No open trial led
  183. Jilin Cancer Hospital

    吉林省肿瘤医院Changchun

    0 papers led
    No open trial led
  184. Linyi Cancer Hospital

    临沂市肿瘤医院Linyi

    0 papers led
    No open trial led
  185. 0 papers led
    No open trial led
  186. Nantong Tumor Hospital

    南通市肿瘤医院Nantong

    0 papers led
    No open trial led
  187. Qingdao Central Hospital

    康复大学青岛中心医院Qingdao

    0 papers led
    No open trial led
  188. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    0 papers led
    No open trial led
  189. 0 papers led
    No open trial led
  190. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    0 papers led
    No open trial led
  191. Suining Central Hospital

    遂宁市中心医院Suining

    0 papers led
    No open trial led
  192. 0 papers led
    No open trial led

By university or health system 55

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Zhengzhou University

    郑州大学Zhengzhou

    203 papers led
    6 hospitals
  2. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    200 papers led
    5 hospitals
  3. Sun Yat-sen University

    中山大学Guangzhou

    179 papers led
    6 hospitals
  4. Hebei Medical University

    河北医科大学Shijiazhuang

    134 papers led
    6 hospitals
  5. Fudan University

    复旦大学Shanghai

    109 papers led
    6 hospitals
  6. Nanjing Medical University

    南京医科大学Nanjing

    108 papers led
    6 hospitals
  7. Fujian Medical University

    福建医科大学Fuzhou

    105 papers led
    6 hospitals
  8. Shandong First Medical University

    山东第一医科大学Jinan

    104 papers led
    6 hospitals
  9. Peking University Health Science Center

    北京大学医学部Beijing

    90 papers led
    5 hospitals
  10. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    82 papers led
    6 hospitals
  11. Sichuan University (West China)

    四川大学华西Chengdu

    72 papers led
    2 hospitals
  12. Shantou University Medical College

    汕头大学医学院Shantou

    66 papers led
    1 hospital
  13. Tianjin Medical University

    天津医科大学Tianjin

    56 papers led
    4 hospitals
  14. 55 papers led
    2 hospitals
  15. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    50 papers led
    1 hospital
  16. Shandong University

    山东大学Jinan

    49 papers led
    5 hospitals
  17. Soochow University

    苏州大学Suzhou

    41 papers led
    6 hospitals
  18. Air Force Medical University

    空军军医大学Xi'an

    37 papers led
    3 hospitals
  19. Xinjiang Medical University

    新疆医科大学Urumqi

    37 papers led
    2 hospitals
  20. Capital Medical University

    首都医科大学Beijing

    32 papers led
    6 hospitals
  21. Wenzhou Medical University

    温州医科大学Wenzhou

    30 papers led
    6 hospitals
  22. Anhui Medical University

    安徽医科大学Hefei

    29 papers led
    6 hospitals
  23. Xi'an Jiaotong University

    西安交通大学Xi'an

    28 papers led
    5 hospitals
  24. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    27 papers led
    1 hospital
  25. Nanjing University

    南京大学Nanjing

    26 papers led
    5 hospitals
  26. Naval Medical University

    海军军医大学Shanghai

    26 papers led
    3 hospitals
  27. Tongji University

    同济大学Shanghai

    25 papers led
    6 hospitals
  28. Chongqing Medical University

    重庆医科大学Chongqing

    22 papers led
    3 hospitals
  29. Nantong University

    南通大学Nantong

    22 papers led
    1 hospital
  30. China Medical University (Shenyang)

    中国医科大学Shenyang

    20 papers led
    5 hospitals
  31. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    20 papers led
    3 hospitals
  32. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    20 papers led
    6 hospitals
  33. Central South University (Xiangya)

    中南大学湘雅Changsha

    19 papers led
    4 hospitals
  34. 19 papers led
    1 hospital
  35. Xuzhou Medical University

    徐州医科大学Xuzhou

    19 papers led
    6 hospitals
  36. Harbin Medical University

    哈尔滨医科大学Harbin

    17 papers led
    4 hospitals
  37. Xiamen University

    厦门大学Xiamen

    16 papers led
    3 hospitals
  38. Wuhan University

    武汉大学Wuhan

    15 papers led
    2 hospitals
  39. Southern Medical University

    南方医科大学Guangzhou

    14 papers led
    3 hospitals
  40. Nanchang University

    南昌大学Nanchang

    12 papers led
    2 hospitals
  41. Southwest Medical University

    西南医科大学Luzhou

    12 papers led
    1 hospital
  42. Army Medical University

    陆军军医大学Chongqing

    11 papers led
    3 hospitals
  43. Guangzhou Medical University

    广州医科大学Guangzhou

    11 papers led
    4 hospitals
  44. Jinan University

    暨南大学Guangzhou

    11 papers led
    3 hospitals
  45. Qingdao University

    青岛大学Qingdao

    9 papers led
    2 hospitals
  46. 9 papers led
    2 hospitals
  47. Guangxi Medical University

    广西医科大学Nanning

    8 papers led
    3 hospitals
  48. Jilin University

    吉林大学Changchun

    7 papers led
    2 hospitals
  49. Chongqing University

    重庆大学Chongqing

    6 papers led
    3 hospitals
  50. Jiangnan University

    江南大学Wuxi

    6 papers led
    1 hospital
  51. Bengbu Medical University

    蚌埠医科大学Bengbu

    5 papers led
    1 hospital
  52. Guangdong Medical University

    广东医科大学Zhanjiang

    5 papers led
    2 hospitals
  53. Kunming Medical University

    昆明医科大学Kunming

    4 papers led
    2 hospitals
  54. Ningxia Medical University

    宁夏医科大学Yinchuan

    4 papers led
    1 hospital
  55. Shenzhen University

    深圳大学Shenzhen

    3 papers led
    2 hospitals

190

open trials on oesophageal squamous cell carcinoma in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 168 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07244978

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  2. Recruiting
    Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07246330

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  3. Recruiting
    A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07385001

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  4. Recruiting
    Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07403136

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  5. Recruiting
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07405151

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou

  6. Recruiting
    Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07452601

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  7. Recruiting
    Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07457528

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  8. Recruiting
    QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07463573

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  9. Recruiting
    Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07505186

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  10. Recruiting
    Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07519486

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  11. Recruiting
    A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Registry
    NCT07554456

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  12. Recruiting
    Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07559045

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Zunyi Medical UniversityZunyi

  13. Recruiting
    Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07595770

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  14. Recruiting
    Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07627347

    Age 18 years to 70 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  15. Recruiting
    Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07629817

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  16. Recruiting
    PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07697859

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  17. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  18. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  19. Recruiting
    A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07751341

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou

  20. Recruiting
    Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07787273

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  21. Recruiting
    Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07811752

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  22. Recruiting
    Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07858630

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  23. Recruiting
    A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07863141

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  24. Recruiting
    Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07892833

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu

  25. Recruiting
    A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06356688

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  26. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  27. Recruiting
    A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT06753747

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  28. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06769113

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  29. Recruiting
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06780111

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou

  30. Recruiting
    A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06843889

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  31. Recruiting
    A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06869213

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  32. Recruiting
    Neoadjuvant QL1706 Therapy for ESCC
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06908382

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Provincial HospitalJinan

  33. Recruiting
    Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06912074

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  34. Recruiting
    CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06964568

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  35. Recruiting
    Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07038629

    Age 70 years to 90 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  36. Recruiting
    QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07049185

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  37. Recruiting
    Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07054086

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  38. Recruiting
    Oncolytic Virus in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07061704

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  39. Recruiting
    Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07086469

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  40. Recruiting
    Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07088354

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  41. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07090499

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  42. Recruiting
    dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07162506

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  43. Recruiting
    Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07177794

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  44. Recruiting
    Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07188103

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  45. Recruiting
    Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07263919

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteXi'an

  46. Recruiting
    Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07266480

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  47. Recruiting
    The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07290010

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  48. Recruiting
    Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07317609

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  49. Recruiting
    Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07339488

    Age 18 years to 75 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  50. Recruiting
    Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07435454

    Age 70 years to Not stated (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  51. Recruiting
    KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07481058

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  52. Recruiting
    Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07530094

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  53. Recruiting
    Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07622797

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Henan University of Science and TechnologyLuoyang

  54. Recruiting
    Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCC
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07796113

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  55. Recruiting
    A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
    Phase
    Phase 3
    Started
    2024-02
    Registry
    NCT06194734

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  56. Recruiting
    Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06272214

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  57. Recruiting
    Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06304350

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  58. Recruiting
    Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06339619

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  59. Recruiting
    Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06342167

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan

  60. Recruiting
    PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06354140

    Age 18 years to 75 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  61. Recruiting
    Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06385730

    Age 76 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  62. Recruiting
    Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06408584

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  63. Recruiting
    Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06413342

    Age 70 years to 85 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  64. Recruiting
    Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06421376

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesAnyang, Beijing, Xinxiang

  65. Recruiting
    Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06430658

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  66. Recruiting
    Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06446726

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  67. Recruiting
    Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06452602

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  68. Recruiting
    A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06463834

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  69. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  70. Recruiting
    AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06489197

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  71. Recruiting
    Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06509568

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  72. Recruiting
    Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06510660

    Age 18 years to 70 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  73. Recruiting
    Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06561178

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  74. Recruiting
    Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2024-02
    Registry
    NCT06563869

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  75. Recruiting
    Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06576973

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  76. Recruiting
    Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06596954

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  77. Recruiting
    Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06601309

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  78. Recruiting
    Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06602843

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  79. Recruiting
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06637163

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin

  80. Recruiting
    Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06646588

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  81. Recruiting
    Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06663059

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  82. Recruiting
    Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06675201

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  83. Recruiting
    TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06676449

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  84. Recruiting
    Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06684600

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  85. Recruiting
    Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06698692

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  86. Recruiting
    A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06709417

    Age 20 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  87. Recruiting
    Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06907602

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  88. Recruiting
    Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06988956

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  89. Recruiting
    Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT07016724

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  90. Recruiting
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT07430579

    Age 18 years to 80 years (registered criteria)

    Led by Second Hospital of Shandong University; 1 listed hospital as study siteJinan

  91. Recruiting
    Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT07437898

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Putian UniversityPutian

  92. Recruiting
    Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT07699185

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  93. Recruiting
    Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
    Phase
    N/A
    Started
    2023-05
    Registry
    NCT03734952

    Age 18 years to 65 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  94. Recruiting
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    Phase
    Phase 1/Phase 2
    Started
    2023-05
    Registry
    NCT05319730

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou

  95. Recruiting
    Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05738434

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  96. Recruiting
    Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-07
    Registry
    NCT05833594

    Age 18 years to 85 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  97. Recruiting
    Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT05894369

    Age 18 years to 80 years (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  98. Recruiting
    A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2023-07
    Registry
    NCT05919030

    Age 18 years to Not stated (registered criteria)

    Led by Renmin Hospital of Wuhan UniversityWuhan

  99. Recruiting
    Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Registry
    NCT05937438

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  100. Recruiting
    Minimally Residual of Esophageal Cancer 001
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT05952661

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  101. Recruiting
    Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-01
    Registry
    NCT05978193

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 1 listed hospital as study siteShanghai

  102. Recruiting
    Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT05984342

    Age 18 years to 70 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  103. Recruiting
    Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06056336

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  104. Recruiting
    Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-01
    Registry
    NCT06173986

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  105. Recruiting
    A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06190639

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  106. Recruiting
    Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06354218

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  107. Recruiting
    Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06410651

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  108. Recruiting
    Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06429839

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  109. Recruiting
    Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT06718205

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  110. Recruiting
    Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT07266493

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  111. Recruiting
    Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT07549100

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Provincial HospitalJinan

  112. Recruiting
    Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
    Phase
    Phase 2/Phase 3
    Started
    2022-03
    Registry
    NCT04973306

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  113. Recruiting
    A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05182944

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  114. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  115. Recruiting
    Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05214222

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  116. Recruiting
    Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
    Phase
    Phase 2
    Started
    2022-06
    Registry
    NCT05252078

    Age 18 years to Not stated (registered criteria)

    Led by Jiangxi Cancer HospitalNanchang

  117. Recruiting
    Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
    Phase
    N/A
    Started
    2022-04
    Registry
    NCT05327517

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  118. Recruiting
    PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05357846

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  119. Recruiting
    Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
    Phase
    Not given
    Started
    2022-08
    Registry
    NCT05392413

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  120. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

  121. Recruiting
    Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2022-08
    Registry
    NCT05495152

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  122. Recruiting
    Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT05507411

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

  123. Recruiting
    Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-05
    Registry
    NCT05515315

    Age 18 years to 70 years (registered criteria)

    Led by 900th Hospital of the PLA Joint Logistics Support ForceFuzhou

  124. Recruiting
    Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT06006650

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  125. Recruiting
    Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT06190782

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  126. Recruiting
    Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
    Phase
    Phase 3
    Started
    2021-01
    Registry
    NCT04415853

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  127. Recruiting
    Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
    Phase
    Phase 3
    Started
    2021-12
    Registry
    NCT04807673

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  128. Recruiting
    Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
    Phase
    N/A
    Started
    2021-06
    Registry
    NCT05775419

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  129. Recruiting
    An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2021-03
    Registry
    NCT07080437

    Age 70 years to Not stated (registered criteria)

    Led by Chongqing University Three Gorges HospitalChongqing

  130. Recruiting
    Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
    Phase
    Phase 3
    Started
    2020-04
    Registry
    NCT04280822

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  131. Recruiting
    Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
    Phase
    N/A
    Started
    2020-01
    Registry
    NCT04519905

    Age 76 years to Not stated (registered criteria)

    Led by Huadong Hospital, Fudan University; 1 listed hospital as study siteNanjing, Shanghai

  132. Recruiting
    Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2020-12
    Registry
    NCT05740995

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  133. Recruiting
    Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2019-04
    Registry
    NCT03964753

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  134. Recruiting
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2019-09
    Registry
    NCT04135664

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 5 listed hospitals as study sitesNanchang, Shanghai, Tianjin

  135. Recruiting
    Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
    Phase
    Phase 3
    Started
    2019-10
    Registry
    NCT04138212

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  136. Recruiting
    Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2019-12
    Registry
    NCT04174079

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  137. Recruiting
    Chemoradiotherapy in Unresectable Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-10
    Registry
    NCT04278287

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing

  138. Recruiting
    Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
    Phase
    N/A
    Started
    2016-11
    Registry
    NCT02972372

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Henan University of Science and Technology; 1 listed hospital as study siteAnyang, Luoyang

  139. Recruiting
    Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT04522687

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  140. Not yet recruiting
    Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT06952621

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  141. Not yet recruiting
    Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07376876

    Age 18 years to 80 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  142. Not yet recruiting
    Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07403435

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  143. Not yet recruiting
    A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07446335

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  144. Not yet recruiting
    Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07493993

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  145. Not yet recruiting
    SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07524374

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  146. Not yet recruiting
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07531979

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  147. Not yet recruiting
    Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07618910

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  148. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  149. Not yet recruiting
    Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07678580

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu HospitalXi'an

  150. Not yet recruiting
    A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07688291

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  151. Not yet recruiting
    Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07697040

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  152. Not yet recruiting
    Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07701681

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  153. Not yet recruiting
    Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07721103

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  154. Not yet recruiting
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07769658

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou

  155. Not yet recruiting
    Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC
    Phase
    N/A
    Started
    2026-09
    Registry
    NCT07769866

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  156. Not yet recruiting
    An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07770672

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  157. Not yet recruiting
    Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07780721

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Putian UniversityPutian

  158. Not yet recruiting
    A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
    Phase
    Phase 3
    Started
    2026-10
    Registry
    NCT07788001

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  159. Not yet recruiting
    Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07799077

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  160. Not yet recruiting
    Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07822906

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  161. Not yet recruiting
    Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07823270

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  162. Not yet recruiting
    Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06814158

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  163. Not yet recruiting
    Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06861777

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  164. Not yet recruiting
    Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT06861894

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  165. Not yet recruiting
    Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06889402

    Age 18 years to 85 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  166. Not yet recruiting
    Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06903871

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  167. Not yet recruiting
    Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07034118

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  168. Not yet recruiting
    A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07112833

    Age 18 years to 75 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  169. Not yet recruiting
    Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07154108

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  170. Not yet recruiting
    RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06012214

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  171. Not yet recruiting
    A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06487702

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  172. Not yet recruiting
    Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC)
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06681285

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  173. Not yet recruiting
    Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06756841

    Age 20 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  174. Not yet recruiting
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Registry
    NCT06136988

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  175. Not yet recruiting
    A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06152978

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  176. Not yet recruiting
    Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06178211

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  177. Not yet recruiting
    Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05244798

    Age 18 years to 75 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  178. Not yet recruiting
    Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-12
    Registry
    NCT05386056

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  179. Not yet recruiting
    Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05420480

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  180. Enrolling by invitation
    Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06984055

    Age 18 years to 85 years (registered criteria)

    Led by Changhai HospitalShanghai

  181. Enrolling by invitation
    Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07312578

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  182. Enrolling by invitation
    Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07371247

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  183. Enrolling by invitation
    Infiltration Pattern of Locally Advanced ESCC
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07567716

    Age not stated (registered criteria)

    Led by Shanghai Chest HospitalShanghai

  184. Enrolling by invitation
    Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Registry
    NCT06690216

    Age 18 years to Not stated (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  185. Enrolling by invitation
    Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06715501

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Ningbo UniversityNingbo

  186. Enrolling by invitation
    A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06863831

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  187. Enrolling by invitation
    Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT07016737

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  188. Enrolling by invitation
    A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06160557

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

  189. Enrolling by invitation
    Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT06048926

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  190. Enrolling by invitation
    Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2022-06
    Registry
    NCT06303583

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions